Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes

  title={Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes},
  author={Floris Alexander van de Laar},
  journal={Vascular Health and Risk Management},
  pages={1189 - 1195}
Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In… CONTINUE READING